SENSIT TECHNOLOGIES acquired by HALMA

Cellink has finalized a definitive agreement to acquire Scienion in a move designed to fundamentally transform its role in the global diagnostics and pharmaceutical markets. The strategic rationale for this transaction centers on a "vertical-integration" play, merging the target's industry-leading technical operational depth in precision picoliter dispensing with the group’s established global leadership in bioprinting and single-cell handling. This structural alignment provides the organization with the scientific talent and high-performance hardware—specifically the target's proprietary dispensing platforms—required to address the increasing demand for standardized high-throughput production of clinically approved diagnostic devices.

The acquisition of Envea by The Carlyle Group is a strategic move that aims to support the company's growth and expansion plans. The deal is expected to provide Envea with the necessary resources and expertise to further develop its product portfolio and to expand its presence in the global market. The Carlyle Group's investment in Envea is a testament to the company's strong potential for growth and its commitment to innovation and customer satisfaction. The acquisition is also expected to have a positive impact on the environment, as Envea's products and services are designed to help reduce air pollution and to promote sustainable development. The deal is subject to regulatory approvals and is expected to be completed in the coming months. The Carlyle Group's investment in Envea is a significant milestone for the company, and it is expected to have a positive impact on the company's future prospects. The acquisition is also expected to create new opportunities for Envea's employees and customers, as the company continues to grow and expand its operations. The deal is a strategic move that aims to create long-term value for all stakeholders involved, including The Carlyle Group, Envea, and the company's customers and employees.

In one of the largest European LBOs in history, Thyssenkrupp AG agreed to sell its Elevator division to a consortium led by Advent and Cinven for an Enterprise Value of €17.2 billion. The transaction followed a highly competitive auction process where strategic bidders, such as Kone, were sidelined due to significant antitrust risks. To facilitate the deal and maintain a strategic link, Thyssenkrupp reinvested €1.25 billion to retain a minority stake. The sale was a critical move for the German conglomerate to address its high debt levels and offset massive losses in its steel and automotive sectors. As part of the agreement, the buyers provided extensive social guarantees, including the preservation of the German headquarters and existing production sites, securing the support of the IG Metall union and the supervisory board.

The global fluidics leader has successfully finalized a definitive agreement to acquire the total share capital of the target, marking a significant expansion of its technical capabilities within the energy infrastructure segment. This strategic transaction represents a definitive move to incorporate mission-critical flow calibration technology into the group's broader energy division. The strategic rationale for the move centers on the acquirer’s objective to broaden its technical operational depth in custody transfer accuracy, providing a complementary fit to its existing portfolio of pumps and metering systems.

Nordic Capital signed an agreement to acquire Consilium Marine & Safety from its parent company, Consilium AB, in a complex carve-out transaction. The deal includes the transfer of the "Consilium" brand rights to the new standalone entity. The strategic rationale is to liberate the division from the conglomerate structure of the listed parent, allowing it to operate as an independent, focused safety champion. Nordic Capital plans to deploy its operational resources to accelerate growth through R&D investment, commercial excellence initiatives, and a targeted M&A strategy to consolidate the fragmented safety market. The thesis is heavily underpinned by the resilience of the safety market and the attractive recurring revenue profile of the aftermarket business.

The acquisition of Gatan marks a definitive technical reinforcement of the group’s presence in the global analytical instrumentation market. The strategic rationale for this transaction centers on a "portfolio-integration" play, merging the target's industry-leading electron microscopy technologies with the group’s extensive Electronic Instruments Group (EIG) infrastructure. This fusion effectively creates a specialized powerhouse in the high-end research sector, providing the organization with the proprietary cameras, energy filters, and software required to support the world’s most sophisticated laboratory workflows.

The acquisition of BTG marks a significant expansion of technical capabilities within the specialized pulp and paper industry, creating a more comprehensive portfolio for global customers. This strategic operation follows a definitive agreement to integrate specialized sensor and automation technologies into a larger industrial technology group. The merger aims to enhance the delivery of high-value solutions that optimize production efficiency and paper quality on a global scale. By combining deep research and development expertise with extensive full-line industrial manufacturing capabilities, the new partnership is well-positioned to drive innovation in process automation. The transaction is a key element of a broader strategy to strengthen technical leadership in the paper manufacturing sector, particularly through the adoption of advanced digital tools. BTG’s integration into the existing organizational structure will leverage technical synergies to provide more integrated solutions for modern production facilities. This consolidation of expertise supports the ongoing transformation toward smarter, more sustainable industrial operations, providing manufacturers with the tools needed to remain competitive in a rapidly evolving market. The finalization of this agreement underscores a shared vision for technological leadership and the continuous improvement of industrial processes. Both organizations are dedicated to ensuring a smooth transition that protects and enhances the specialized value provided to their respective customer bases over the long term.

Teledyne Technologies Incorporated has successfully completed the acquisition of the gas and flame detection business of 3M. The transaction represents a significant corporate carve,out from 3M’s Safety and Industrial Division. The acquisition includes several global brands such as Oldham, Simtronics, GMI, and Detcon, as well as select products from the Scott Safety line (though 3M retains the Scott Safety brand name itself). Approximately 500 employees joined Teledyne as part of the transition. The strategic rationale for the deal is the high degree of technological and market overlap with Teledyne’s existing environmental instrumentation businesses. While the products are complementary rather than directly competitive, the integration allows Teledyne to offer a broader suite of safety and measurement tools to its global customer base. The acquisition was completed within two months of the initial announcement, highlighting Teledyne's capability in executing complex carve,outs. Management expects the business to be a long,term core component of the group and accretive to GAAP earnings per share.

Agilent has finalized the acquisition of BioTek Instruments in an all-cash transaction, a maneuver designed to fundamentally expand its capabilities in the critical cell analysis technology sector. The strategic rationale for this transaction centers on a "workflow-simplification" play, merging the target's industry-leading expertise in microplate detection and imaging with the group’s established presence in live-cell, real-time analysis. This structural alignment provides the organization with the scientific talent and technological hardware required to address the increasing complexity of immunotherapy and biologics research. This operation allows the group to execute a definitive structural expansion of its biopharma and academic service offerings.

Danaher has finalized an agreement to acquire GE Biopharma in a transformational all-cash transaction, an operation designed to fundamentally redefine the landscape of the global bioprocessing market. The strategic rationale for this transaction centers on a "Bioprocessing-Powerhouse" play, merging the target's industry-leading technical operational depth in chromatography and cell culture with the group’s established life sciences platform and the power of the Danaher Business System. This structural alignment provides the organization with the scientific talent and technological hardware—specifically across upstream and downstream workflows—required to address the surging global demand for biologic drug development.